Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 97 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cialis Clear all
Completed No phase listed Observational Results available

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - PDE5

NCT05039086
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
PDE5 inhibitor, Endothelin Receptor Antagonists
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
13,021 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00386009
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
8
States / cities
Newport Beach, California • Tarzana, California • Middlebury, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2009 · Synced Sep 6, 2026, 4:31 AM EDT
Not yet recruiting Phase 4 Interventional

PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)

NCT07636161
View directory record Official record
Conditions
Type 2 Diabetes, Type 2 Diabetes (T2DM)
Interventions
Eroxon®, tadalafil
Device · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of PDE5 Inhibition on Adipose Metabolism in Humans

NCT04684589
View directory record Official record
Conditions
Obesity
Interventions
Tadalafil 20 MG, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
19 Years to 50 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

NCT01544998
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nesiritide, Tadalafil, Placebo, Saline load
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)

NCT02058095
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Not applicable Interventional Results available

Tadalafil in Treating Patients Undergoing Surgery for Cancer of the Oral Cavity or Oropharynx

NCT00843635
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Tadalafil, Placebo
Drug · Other
Lead sponsor
Donald T. Weed
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2015 · Synced Sep 6, 2026, 4:31 AM EDT
Terminated Phase 4 Interventional Results available

Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study

NCT01275339
View directory record Official record
Conditions
Aortic Stenosis, LV Remodeling, Hypertrophy
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

NCT03993353
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck
Interventions
Pembrolizumab, Tadalafil
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 6, 2026, 4:31 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy

NCT02653833
View directory record Official record
Conditions
Muscular Dystrophy
Interventions
Tadalafil 20 MG, beetroot juice extract
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 2 Interventional

Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual Dysfunction

NCT00707187
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Cialis
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2008 · Synced Sep 6, 2026, 4:31 AM EDT
Completed No phase listed Observational Results available

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
Not listed
Enrollment
1,333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 6, 2026, 4:31 AM EDT
Withdrawn Phase 2 Interventional

Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia

NCT00538564
View directory record Official record
Conditions
Sickle Cell Anemia, Priapism
Interventions
tadalafil, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 45 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2016 · Synced Sep 6, 2026, 4:31 AM EDT
Terminated Phase 3 Interventional Results available

Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure

NCT01910389
View directory record Official record
Conditions
Heart Failure, Pulmonary Hypertension
Interventions
Tadalafil, Placebo for tadalafil
Drug
Lead sponsor
Carelon Research
Other
Eligibility
21 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
62
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 55 more
Source: ClinicalTrials.gov public record
Updated May 3, 2015 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

NCT00422734
View directory record Official record
Conditions
Impotence
Interventions
tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2009 · Synced Sep 6, 2026, 4:31 AM EDT
Terminated Phase 2 Interventional Results available

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

NCT03785210
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, Liver Metastasis
Interventions
nivolumab, tadalafil, oral vancomycin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 4 Interventional Results available

A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).

NCT01305252
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
treprostinil inhalations, tadalafil
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Stanford, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction

NCT02819440
View directory record Official record
Conditions
Healthy, Obese
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 50 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers

NCT00848081
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
28
States / cities
Huntsville, Alabama • Anchorage, Alaska • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

NCT00549302
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
tadalafil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
View directory record Official record
Conditions
Healthy
Interventions
Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 6, 2026, 4:31 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Hezkue®, Hezkue Turbo®, and Commercial Sildenafil Products in Fed Healthy Male Subject

NCT07117383
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
ASP-001.1, ASP-001, Commercial Sildenafil and Sildenafil/Tadalafil Products
Device · Drug
Lead sponsor
Aspargo Labs, Inc
Industry
Eligibility
18 Years to 70 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 6, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

A Study in Benign Prostatic Hyperplasia

NCT01152190
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Chicago, Illinois • Garden City, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 6, 2026, 4:31 AM EDT